Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuraxis (NRXS) Change in Accured Expenses (2022 - 2025)

Historic Change in Accured Expenses for Neuraxis (NRXS) over the last 4 years, with Q3 2025 value amounting to $138170.0.

  • Neuraxis' Change in Accured Expenses rose 15785.48% to $138170.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $726989.0, marking a year-over-year decrease of 1828.95%. This contributed to the annual value of $949693.0 for FY2024, which is 42285.57% up from last year.
  • Latest data reveals that Neuraxis reported Change in Accured Expenses of $138170.0 as of Q3 2025, which was up 15785.48% from $251028.0 recorded in Q2 2025.
  • Over the past 5 years, Neuraxis' Change in Accured Expenses peaked at $592114.0 during Q2 2024, and registered a low of -$755499.0 during Q3 2023.
  • Its 4-year average for Change in Accured Expenses is $92881.5, with a median of $153489.0 in 2023.
  • Within the past 5 years, the most significant YoY rise in Neuraxis' Change in Accured Expenses was 64519.43% (2023), while the steepest drop was 723351.78% (2023).
  • Quarter analysis of 4 years shows Neuraxis' Change in Accured Expenses stood at $16241.0 in 2022, then surged by 645.19% to $121027.0 in 2023, then skyrocketed by 49.56% to $181007.0 in 2024, then fell by 23.67% to $138170.0 in 2025.
  • Its Change in Accured Expenses stands at $138170.0 for Q3 2025, versus $251028.0 for Q2 2025 and $156784.0 for Q1 2025.